Home > Boards > Free Zone > User's Groups > IPOs + SPACs of Interest

>>> Atai Life Sciences Announces Pricing of Upsized

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
gfp927z Member Profile
 
Followed By 70
Posts 26,414
Boards Moderated 75
Alias Born 03/22/05
160x600 placeholder
Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
By Josh Beckerman
Top Company News of the Day
Netflix Ends Down Nearly 22%, Worst Performer in the S&P 500 and Nasdaq 100 Today -- Data Talk
2-Year Treasury Yield Rises to 0.993% This Week -- Data Talk
10-Year Treasury Yield Falls to 1.747% This Week -- Data Talk
30-Year Treasury Yield Falls to 2.062% This Week -- Data Talk
Wheat Falls as U.S.-Russia Negotiations Continue - Daily Grain Highlights
Front Month Nymex Natural Gas Fell 6.17% This Week to Settle at $3.9990 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.97% This Week to Settle at $2.4424 -- Data Talk
GDP Seen +5.8% in 4Q -- Data Week Ahead
Canada's Omicron Infections May Have Peaked But Hospitalizations Rise, Health Officer Says
Coinbase Global Down Over 12%, on Track for Record Low Close and Record Percent Decrease -- Data Talk
EURO STOXX 50 Index Ends the Week 1.00% Lower at 4229.56 -- Data Talk
CAC 40 Index Ends the Week 1.04% Lower at 7068.59 -- Data Talk
STOXX Europe 50 Index Ends the Week 0.44% Lower at 3781.98 -- Data Talk
STOXX Europe 600 Index Ends the Week 1.40% Lower at 474.44 -- Data Talk
FTSE 100 Index Ends the Week 0.65% Lower at 7494.13 -- Data Talk
DAX Ends the Week 1.76% Lower at 15603.88 -- Data Talk
FTSE 100 Ends the Week Lower, Losing Year-to-Date Gains
Ecolab Down Nearly 6%, on Track for Largest Percent Decrease Since July 2020 -- Data Talk
Intuitive Surgical Down Nearly 7%, on Pace for Largest Percent Decrease Since April 2020 -- Data Talk
GM Expanding Production of Electric Motor Parts in NY State
Walt Disney Worst Performer in the DJIA So Far Today -- Data Talk
Glaxo Unit Valuation Boost Looks Less Likely as Unilever Walks -- Market Insight
gfp927z   Thursday, 08/26/21 11:13:50 AM
Re: None
Post # of 115 
>>> Atai Life Sciences Announces Pricing of Upsized Initial Public Offering


Yahoo Finance

Atai LIFE SCIENCES

June 17, 2021


https://finance.yahoo.com/news/atai-life-sciences-announces-pricing-032100058.html


BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. All common shares are being offered by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, are expected to be $225.0 million. In addition, atai has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 common shares at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on June 22, 2021, subject to customary closing conditions.

atai’s common shares are expected to begin trading on the Nasdaq Global Market on June 18, 2021 under the ticker symbol “ATAI.”

Credit Suisse, Citigroup, Cowen, and Berenberg are acting as book-running managers for the proposed offering. Cantor, RBC Capital Markets and Canaccord Genuity are also acting as book-running managers for the proposed offering.

This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146 or by email at prospectus@citi.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by telephone at (833) 297-2926, or by email at

PostSaleManualRequests@broadridge.com; or, Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, New York 10020, or by telephone at +1 (646) 949-9000, or by e-mail at prospectusrequests@berenberg-us.com.

A registration statement relating to the securities being sold in the offering has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on June 17, 2021. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. atai is headquartered in Berlin, with offices in New York and London.

<<<





Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences